709 related articles for article (PubMed ID: 26017279)
1. Tapentadol for chronic musculoskeletal pain in adults.
Santos J; Alarcão J; Fareleira F; Vaz-Carneiro A; Costa J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD009923. PubMed ID: 26017279
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Oxycodone for neuropathic pain and fibromyalgia in adults.
Gaskell H; Moore RA; Derry S; Stannard C
Cochrane Database Syst Rev; 2014 Jun; (6):CD010692. PubMed ID: 24956205
[TBL] [Abstract][Full Text] [Related]
4. Oral tapentadol for cancer pain.
Wiffen PJ; Derry S; Naessens K; Bell RF
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD011460. PubMed ID: 26403220
[TBL] [Abstract][Full Text] [Related]
5. Cannabis-based medicines for chronic neuropathic pain in adults.
Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392
[TBL] [Abstract][Full Text] [Related]
6. Oral or transdermal opioids for osteoarthritis of the knee or hip.
da Costa BR; Nüesch E; Kasteler R; Husni E; Welch V; Rutjes AW; Jüni P
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD003115. PubMed ID: 25229835
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies.
Lange B; von Zabern D; Elling C; Dubois C
Curr Med Res Opin; 2017 Aug; 33(8):1413-1422. PubMed ID: 28537506
[TBL] [Abstract][Full Text] [Related]
8. Opioids for neuropathic pain.
McNicol ED; Midbari A; Eisenberg E
Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD006146. PubMed ID: 23986501
[TBL] [Abstract][Full Text] [Related]
9. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.
Buynak R; Rappaport SA; Rod K; Arsenault P; Heisig F; Rauschkolb C; Etropolski M
Clin Ther; 2015 Nov; 37(11):2420-38. PubMed ID: 26428249
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.
Biondi DM; Xiang J; Etropolski M; Moskovitz B
J Opioid Manag; 2015; 11(5):393-403. PubMed ID: 26535967
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
15. Oxycodone for cancer-related pain.
Schmidt-Hansen M; Bennett MI; Arnold S; Bromham N; Hilgart JS
Cochrane Database Syst Rev; 2015 Feb; (2):CD003870. PubMed ID: 25723351
[TBL] [Abstract][Full Text] [Related]
16. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
17. Oxycodone for cancer-related pain.
Schmidt-Hansen M; Bennett MI; Arnold S; Bromham N; Hilgart JS
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD003870. PubMed ID: 28829910
[TBL] [Abstract][Full Text] [Related]
18. Oxycodone for neuropathic pain in adults.
Gaskell H; Derry S; Stannard C; Moore RA
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010692. PubMed ID: 27465317
[TBL] [Abstract][Full Text] [Related]
19. Topical NSAIDs for chronic musculoskeletal pain in adults.
Derry S; Conaghan P; Da Silva JA; Wiffen PJ; Moore RA
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD007400. PubMed ID: 27103611
[TBL] [Abstract][Full Text] [Related]
20. Opioids compared to placebo or other treatments for chronic low-back pain.
Chaparro LE; Furlan AD; Deshpande A; Mailis-Gagnon A; Atlas S; Turk DC
Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD004959. PubMed ID: 23983011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
